Diagnosis and treatment methods of autoimmune myasthenia gravis : a systematic review

Basit Öğe Kaydı
dc.authorid2517-1717-0002-0000en_US
dc.contributor.authorYangın, Melike Nur
dc.contributor.authorZorlu, Yaşar
dc.contributor.authorSevercan, Feride
dc.date.accessioned2023-10-16T13:21:53Z
dc.date.available2023-10-16T13:21:53Z
dc.date.issued2022en_US
dc.departmentEnstitüler, Lisansüstü Eğitim Enstitüsü, Biyomedikal Bilimler Ana Bilim Dalıen_US
dc.description.abstractMyasthenia Gravis (MG), which is an autoimmune disorder, causes abnormalities in the neuromuscular junction and has a prevalence of 15-20 per 100,000 people. Although skeletal and extraocular muscles are commonly affected by the disease, approximately 10% of patients have severe involvement in the muscles necessary for respiration. A myasthenic crisis may cause life-threatening consequences. The prevalence and incidence of autoimmune MG increase with age. Women’s disease incidence peaks between the ages of 30 and 40, while men’s incidence peaks between the ages of 60 and 80. The existence of autoantibodies against postsynaptic membrane proteins is the most crucial indicator of MG. Anti-AChR (acetylcholine receptor antibody) positive is a distinct feature of MG (% 80). While antiMuSK (muscle-specific kinase antibody) positivity is detected in 1-10% of all patients, LRP4 (low density lipoprotein receptor related protein 4) antibody positivity is seen in 3-25% of MG patients without AChR and MuSK antibodies (anti-LRP4). Despite many methods used in the diagnosis of MG, it is not possible to make the diagnosis in some patients because of conditions that may vary from patient to patient, such as fluctuation in symptoms and clinical findings. Rapid diagnosis is crucial in patients with MG, because effective treatment must begin as early as possible to prevent potentially fatal complications. Moreover, rapid diagnosis of patients and determination of the patient’s subtype is an important step in the treatment process. Therefore, the aim of this study is to summarize the techniques used in the diagnosis and treatment of MG which is one of the rare diseases.en_US
dc.identifier.citationYangın, M. N., Zorlu, Y., Severcan, F. (2022). Diagnosis and treatment methods of autoimmune myasthenia gravis : a systematic review. AURUM Journal of Health Sciences, 4(2), 104-116.en_US
dc.identifier.endpage116en_US
dc.identifier.issn1234-5678
dc.identifier.issue2en_US
dc.identifier.startpage104en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12939/4119
dc.identifier.volume4en_US
dc.institutionauthorYangın, Melike Nur
dc.institutionauthorSevercan, Feride
dc.language.isoen
dc.publisherAltınbaş Üniversitesien_US
dc.relation.ispartofAURUM Journal of Health Sciences
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - İdari Personel ve Öğrencien_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMyasthenia Gravisen_US
dc.subjectDiagnosis Methodsen_US
dc.subjectTreatment Methodsen_US
dc.subjectRare Diseasesen_US
dc.subjectNeuromuscular Disordersen_US
dc.subjectAutoimmune Disordersen_US
dc.titleDiagnosis and treatment methods of autoimmune myasthenia gravis : a systematic review
dc.typeReview Article

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
49-61.pdf
Boyut:
102.04 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

2022 - Cilt 4 - Sayı 2